{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:46:11Z","timestamp":1777182371700,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009515"],"award-info":[{"award-number":["T32CA009515"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.cllc.2022.03.013","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:10:11Z","timestamp":1651198211000},"page":"446-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-8356","authenticated-orcid":false,"given":"Cristina M.","family":"Merkhofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boryana","family":"Eastman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-3603","authenticated-orcid":false,"given":"Isabella","family":"Densmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9581-4901","authenticated-orcid":false,"given":"Lia M.","family":"Halasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tresa","family":"McGranahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Baik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.03.013_bib0001","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.03.013_bib0003","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/1759-7714.13296","article-title":"Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor","volume":"11","author":"Kwon","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2022.03.013_bib0004","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2022.03.013_bib0005","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11060-013-1199-y","article-title":"Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung","volume":"115","author":"Lee","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0008","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0009","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2018.11.022","article-title":"Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer","volume":"127","author":"Wu","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.03.013_bib0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/1759-7714.12188","article-title":"Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer","volume":"6","author":"Xu","year":"2015","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2022.03.013_bib0012","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/cam4.2156","article-title":"The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute","volume":"8","author":"Yan","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.cllc.2022.03.013_bib0013","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-Mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.03.013_bib0014","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0015","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0017","first-page":"636","article-title":"Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States","volume":"7","author":"Adil","year":"2020","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.cllc.2022.03.013_bib0018","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-013-1160-0","article-title":"Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer","volume":"114","author":"Ray","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cllc.2022.03.013_bib0019","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3111\/13696998.2016.1138962","article-title":"The economic burden of brain metastasis among lung cancer patients in the United States","volume":"19","author":"Guerin","year":"2016","journal-title":"J Med Econ"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:12:37Z","timestamp":1761505957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1525730422000560"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.03.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}